Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.69+0.06 (+0.90%)
Close on Nov 17, 2026Market cap $441.88MP/E –Yield –
Evolus total assets
Total assets on the balance sheet at the end of each period.
Evolus's total assets was $248.02M at Jun 30, 2026. For fiscal 2025 it was $225.87M, down 2.9% from the year before. The highest annual figure on record is $257.48M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $225.87M | -2.9% |
| FY2024 | Dec 31, 2024 | $232.57M | +23.1% |
| FY2023 | Dec 31, 2023 | $189.00M | +6.2% |
| FY2022 | Dec 31, 2022 | $177.98M | -30.9% |
| FY2021 | Dec 31, 2021 | $257.48M | +23.2% |
| FY2020 | Dec 31, 2020 | $209.07M | -13.0% |
| FY2019 | Dec 31, 2019 | $240.44M | +39.9% |
| FY2018 | Dec 31, 2018 | $171.84M | +12.9% |
| FY2017 | Dec 31, 2017 | $152.23M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $248.02M | +8.4% |
| Q1 FY2026 | Mar 31, 2026 | $220.65M | +3.4% |
| Q4 FY2025 | Dec 31, 2025 | $225.87M | -2.9% |
| Q3 FY2025 | Sep 30, 2025 | $219.00M | -4.6% |
| Q2 FY2025 | Jun 30, 2025 | $228.80M | -2.1% |
| Q1 FY2025 | Mar 31, 2025 | $213.36M | -5.7% |
| Q4 FY2024 | Dec 31, 2024 | $232.57M | +23.1% |
| Q3 FY2024 | Sep 30, 2024 | $229.61M | +36.7% |
| Q2 FY2024 | Jun 30, 2024 | $233.77M | +38.3% |
| Q1 FY2024 | Mar 31, 2024 | $226.18M | +41.2% |
| Q4 FY2023 | Dec 31, 2023 | $189.00M | +6.2% |
| Q3 FY2023 | Sep 30, 2023 | $167.97M | -12.8% |
| Q2 FY2023 | Jun 30, 2023 | $168.98M | -19.9% |
| Q1 FY2023 | Mar 31, 2023 | $160.24M | -27.4% |
| Q4 FY2022 | Dec 31, 2022 | $177.98M | -30.9% |
| Q3 FY2022 | Sep 30, 2022 | $192.72M | -10.5% |
| Q2 FY2022 | Jun 30, 2022 | $210.92M | -12.1% |
| Q1 FY2022 | Mar 31, 2022 | $220.66M | +40.4% |
| Q4 FY2021 | Dec 31, 2021 | $257.48M | +23.2% |
| Q3 FY2021 | Sep 30, 2021 | $215.22M | -0.3% |
| Q2 FY2021 | Jun 30, 2021 | $239.86M | +23.3% |
| Q1 FY2021 | Mar 31, 2021 | $157.20M | -26.6% |
| Q4 FY2020 | Dec 31, 2020 | $209.07M | -13.0% |
| Q3 FY2020 | Sep 30, 2020 | $215.78M | +18.1% |
| Q2 FY2020 | Jun 30, 2020 | $194.54M | -4.1% |
| Q1 FY2020 | Mar 31, 2020 | $214.15M | -3.1% |
| Q4 FY2019 | Dec 31, 2019 | $240.44M | +39.9% |
| Q3 FY2019 | Sep 30, 2019 | $182.67M | -0.4% |
| Q2 FY2019 | Jun 30, 2019 | $202.78M | +66.3% |
| Q1 FY2019 | Mar 31, 2019 | $220.93M | +73.4% |
| Q4 FY2018 | Dec 31, 2018 | $171.84M | +12.9% |
| Q3 FY2018 | Sep 30, 2018 | $183.38M | – |
| Q2 FY2018 | Jun 30, 2018 | $121.93M | – |
| Q1 FY2018 | Mar 31, 2018 | $127.40M | – |
| Q4 FY2017 | Dec 31, 2017 | $152.23M | – |
See a number that looks wrong?